Cognition Therapeutics’ dementia drug showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients ...

Results from the long-term extension of the Phase III TRAILBLAZER-ALZ 2 trial (NCT04437511) showed sustained benefits with ...

The trial failed to achieve statistical significance in its goal of improved MCCB neurocognitive composite scores.

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

Cognition Therapeutics Reports Improvement In Cognitive Outcomes In Phase 2 SHINE Study In AD. July 29, 2024 — 08:37 am EDT Written by RTTNews.com for RTTNews -> ...

To fill that gap, Dr. Cherng and his colleagues pooled retrospective data from 288 patients with long-term cognitive testing data who participated in three large, randomized phase III clinical ...

Two-Phase Study Leads to Monteloeder's Newest Nootropic for Cognitive Performance Provided by PR Newswire Feb 25, 2025 4:00am ...

INmune Bio Reports Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease, Identifying Subpopulations with Cognitive Benefits June 30, 2025 — 07:42 am EDT ...

“We are excited to advance MT1988 into Phase II trials, where we aim to demonstrate clinical proof of concept in improving cognitive function in patients living with schizophrenia and related ...

The ERUDITE study was the second Phase 2 trial for luvadaxistat. It failed to replicate the cognitive endpoints data seen in the earlier INTERACT™ study, due in part to the large variability ...